More capital isn't always better. An excess of funding can lead to a lack of focus, wasteful spending, and a reluctance to make tough choices—a form of moral hazard. It's crucial to match the amount of capital to a founder's ability to deploy it effectively without losing discipline.

Raising too much money at a high valuation puts a "bogey on your back." It forces a "shoot the moon" strategy, which can decrease capital efficiency, make future fundraising harder, and limit potential exit opportunities by making the company too expensive for acquirers.

Beyond product-market fit, there is "Founder-Capital Fit." Some founders thrive with infinite capital, while for others it creates a moral hazard, leading to a loss of focus and an inability to make hard choices. An investor's job is to discern which type of founder they're backing before deploying capital that could inadvertently ruin the company.

Accepting significant capital before establishing a repeatable growth model is dangerous. It leads to premature salary inflation, aggressive hiring disconnected from revenue, cultural dilution, and a false sense of success that erodes the team’s grit and hunger.

While capital is necessary, an overabundance is dangerous. Large secondaries can make founders comfortable and misaligned with investors. Excessive primary capital leads to bloat, unfocused strategy, and removes the pressure that drives invention. This moral hazard often leads to worse outcomes than being capital-constrained.

The first question in any fundraising or M&A discussion is always, 'What was your last round price?' An inflated number creates psychological friction and can halt negotiations before they begin. Founders should optimize for a valuation that allows for a clear up-round, not just the highest price today.

Accepting too high a valuation can be a fatal error. The first question in any subsequent fundraising or M&A discussion will be about the prior round's price. An unjustifiably high number immediately destroys the psychology of the new deal, making it nearly impossible to raise more capital or sell the company, regardless of progress.

Venture rounds are compressing and conflating, with massive "seed" rounds of $30M+ essentially combining a seed and Series A. This sets a dangerous trap: the expectations for your next funding round will be equivalent to those of a traditional Series B company, dramatically raising the bar for growth.

Setting an overly optimistic valuation for a pre-revenue friends-and-family round can create a 'valuation trap.' If you later need a structured seed round from an accelerator with standardized (and likely lower) terms, your initial investors may veto the necessary 'down round,' killing the deal and your access to capital.